Medication Effects on Obsessions and Compulsions

Background: Lamotrigine is a phenyltriazine medication that has been approved by the United States Food and Drug Administration as monotherapy and as an adjunctive agent for the treatment of seizure disorder. It was later approved by the FDA for the treatment of bipolar disorder. Lamotrigine is generally well tolerated by patients, but some serious symptoms can occur during treatment. These severe side effects include rashes and multi-organ failure. Lamotrigine has also been associated with the development of mental status changes, frequently when used concurrently with other medications that may impact the metabolism of lamotrigine. Objective: To present the case of a 65-year-old man being treated with lamotrigine and valproic acid who developed mental status changes after the addition of sertraline to his medication regimen, and to compare this case to existing cases reported in the literature. Discussion: Our case adds to the existing literature by demonstrating that patients may experience adverse medication effects despite lamotrigine levels that are normally considered to be in the therapeutic range, highlighting the importance of clinical correlation when obtaining medication levels. Conclusion: Clinicians should use caution interpreting lamotrigine levels when working up delirium, as normal levels may not rule out the development of lamotrigine toxicity.

Download Full-text

Epilepsy and Medication Effects on the Pattern Visual Evoked Potential*

Documenta Ophthalmologica ◽

10.1007/s10633-005-7350-0 ◽

2005 ◽

Vol 110 (1) ◽

pp. 121-131 ◽

Cited By ~ 13

Author(s):

Andrew M. Geller ◽

H. Ken. Hudnell ◽

Bradley V. Vaughn ◽

John A. Messenheimer ◽

William K. Boyes

Keyword(s):

Visual Evoked Potential ◽

Evoked Potential ◽

Pattern Visual Evoked Potential ◽

Medication Effects ◽

Visual Evoked

Download Full-text

A Review of past and Current Pharmacological Intervention in the Treatment of Emotionally Disturbed Children and Adolescents

Behavioral Disorders ◽

10.1177/019874297900500110 ◽

1979 ◽

Vol 5 (1) ◽

pp. 60-69 ◽

Cited By ~ 3

Author(s):

James E. Wilson ◽

Steven D. Sherrets

Keyword(s):

Children And Adolescents ◽

Behavioral Problems ◽

Emotionally Disturbed ◽

Emotional And Behavioral Problems ◽

Pharmacological Intervention ◽

Test Results ◽

Treatment Team ◽

Team Members ◽

Medication Effects ◽

Emotionally Disturbed Children

Increasingly, seriously handicapped students are returning to the schools and the use of psychotropic medications is on the rise with these and other emotionally disturbed children and adolescents. In an effort to improve the dialogue and cooperation within the physician/educator terms an overview of the history, philosophy, current practices and a look at the future of neurochemical treatments of children with emotional and behavioral problems, is presented. A separate review of available literature concerning medication effects on cognitive functioning and test results is presented. Psycho-pharmacology is and can be a useful treatment; however, the available supporting literature that has already been developed with adults is still largely missing with children and adolescents. Guidelines for the treatment team members to help assure proper prescribing and monitoring of medications to achieve maximum therapeutic effect with minimal side-effects are reviewed.

Download Full-text

SSRI use in pregnancy: Evaluating the risks and benefits

South African Journal of Psychiatry ◽

10.4102/sajpsychiatry.v21i2.587 ◽

2015 ◽

Vol 21 (2) ◽

pp. 6

Author(s):

Elsa Du Toit ◽

Eileen Thomas ◽

Liezl Koen ◽

Bavi Vythilingum ◽

Stoffel Grobler ◽

...

Keyword(s):

Antidepressant Treatment ◽

Severe Depression ◽

Evidence Base ◽

Current Evidence ◽

Benefit Analysis ◽

Medication Effects ◽

Current Evidence Base ◽

Pregnancy And Lactation ◽

Potential Risks ◽

Risk Benefit Analysis

<p>Selective serotonin reuptake inhibitor (SSRI) antidepressants are considered the primary pharmacological treatment for moderate to severe depression during pregnancy.<span><em> </em></span>Data regarding the safety of their use during pregnancy remain controversial and conflicting. Decisions regarding the prescription of antidepressant treatment are often fraught with concern around potential harmful medication effects on the pregnancy, fetus and infant. Information on potential risks remains extremely varied and inconsistent across sources. This lack of clarity regarding drug safety brings significant uncertainty not only for treating physicians, but also for women seeking information about depression during pregnancy. This review aims to summarise and evaluate the current evidence base and to aid clinicians in performing a risk/benefit analysis for SSRI use during pregnancy and lactation.</p><div> </div>

Download Full-text

Visuomotor Activation of Inhibition-Processing in Pediatric Obsessive Compulsive Disorder: A Magnetoencephalography Study

Frontiers in Psychiatry ◽

10.3389/fpsyt.2021.632736 ◽

2021 ◽

Vol 12 ◽

Author(s):

Eman Nishat ◽

Colleen Dockstader ◽

Anne L. Wheeler ◽

Thomas Tan ◽

John A. E. Anderson ◽

...

Keyword(s):

Task Performance ◽

Obsessive Compulsive Disorder ◽

Response Inhibition ◽

Regional Differences ◽

Children And Youth ◽

Obsessive Compulsive ◽

Compulsive Disorder ◽

Medication Effects ◽

Imaging Research ◽

Inhibition Performance

Background: Response inhibition engages the cortico-striato-thalamo-cortical (CSTC) circuit, which has been implicated in children, and youth with obsessive compulsive disorder (OCD). This study explored whether CSTC engagement during response inhibition, measured using magnetoencephalography (MEG), differed in a sample of medication-naïve youth with OCD, compared to typically developing controls (TDC).Methods: Data was analyzed in 17 medication-naïve children and youth with OCD (11.7 ± 2.2 SD years) and 13 TDC (12.6 ± 2.2 SD years). MEG was used to localize and characterize neural activity during a Go/No-Go task. Task performance on Go/No-Go conditions and regional differences in amplitude of activity during Go and No-Go condition between OCD vs. TDC were examined using two-sample t-tests. Post-hoc analysis with Bayesian t-tests was used to estimate the certainty of outcomes.Results: No differences in Go/No-Go performance were found between OCD and TDC groups. In response to the visual cue presented during the Go condition, participants with OCD showed significantly increased amplitude of activity in the primary motor (MI) cortex compared to TDC. In addition, significantly reduced amplitude of PCu was found following successful stopping to No-Go cues in OCD vs. TDC during No-Go task performance. Bayesian t-tests indicated high probability and large effect sizes for the differences in MI and PCu amplitude found between groups.Conclusion: Our preliminary study in a small medication-naïve sample extends previous work indicating intact response inhibition in pediatric OCD. While altered neural response in the current study was found during response inhibition performance in OCD, differences localized to regions outside of the CSTC. Our findings suggest that additional imaging research in medication-naïve samples is needed to clarify regional differences associated with OCD vs. influenced by medication effects, and suggest that MEG may be sensitive to detecting such differences.

Download Full-text

P362 Longitudinal antibody response to SARS-CoV-2 infection and antibody responses to COVID-19 vaccination in Inflammatory Bowel Disease patients receiving biologics

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjab076.486 ◽

2021 ◽

Vol 15 (Supplement_1) ◽

pp. S380-S381

Author(s):

S Y Wong ◽

R Dixon ◽

S Gold ◽

M Vicky ◽

D Helmus ◽

...

Keyword(s):

New York ◽

Immune Responses ◽

Antibody Responses ◽

Large Hospital ◽

Nucleocapsid Proteins ◽

Medication Effects ◽

Vaccine Trials ◽

Antibody Titres ◽

Inflammatory Bowel ◽

Hospital Center

Abstract Background Given that IBD patients were excluded from COVID-19 vaccine trials, there is a lack of vaccine efficacy data in this population. In this study, we evaluated longitudinal serological responses to SARS-CoV-2 infection as well as to COVID-19 vaccination in IBD patients. Methods We collected clinical data and sera from IBD patients enrolled in an observational SARS-CoV-2 sero-surveillance study at our large hospital center in New York City during routine infusions and clinic visits. To distinguish between infection and vaccination, sera was collected prior to vaccination where possible, and all sera was tested for both antibodies to SARS-CoV-2-specific RBD, the target of current available vaccines in the U.S., and nucleocapsid proteins. Results Our results reveal waning antibody titres in 13 of 16 (81%) patients infected with SARS-CoV-2 over a course of 6-7 months. Of 48 vaccinated patients, 16 patients completed vaccine schedules with two doses, and all 16 (100%) achieved seroconversion above the threshold required for convalescent plasma donation. Conclusion While antibody responses to infection in IBD patients have questionable stability, completion of the COVID-19 vaccine series in IBD patients results in robust serological responses. To our knowledge is the first data confirming adequate serological responses to COVID-19 vaccination in IBD patients with and without biologic medications. Studies are needed to assess adequacy of dosing schedules, medication effects, measurement of cell-mediated responses, durability of immune responses, and clinical efficacy of COVID-19 vaccines in IBD patients.

Download Full-text